Australia will require all international visitors to have an approved vaccination against the CCP Virus before they board Qantas flights to and from Australia.

As soon as an accepted vaccine for the CCP Virus becomes available for public use, passengers on Qantas international flights will be required to take the jab. No jab, no travel.

Australian airline Qantas is looking at changing its terms and conditions to include, “For international travelers that we will ask people to have a vaccination before they can get on the aircraft,” CEO Alan Joyce said.

The plan to include the CCP Virus vaccination proof in its terms and conditions will primarily be for international travelers once approved. Still, it may also become a condition of domestic travel.

“Whether you need that domestically, we’ll have to see what happens with COVID-19 [the CCP Virus] in the market, but certainly for international visitors coming out and people leaving the country, we think that’s a necessity,” Joyce said in a Monday interview with the Australian news program “A Current Affair.”

Other airlines are likely to follow suit, says Joyce, and it could be enforced with a digital “vaccination passport” to indicate the vaccine they have received, to ensure it’s “acceptable to the country you’re traveling to.”

“I’m talking to my colleagues in other airlines around the globe, and I think it’s going to be a common theme across the board,” Joyce said during the interview. “There’s a lot of logistics, a lot of technology that’ll be needed to be put in place to make this happen, but the airlines and the governments are working on this as we speak.”

Domestic travel for Qantas has reopened, and Joyce said all of the Australian states’ borders are expected to be open by Christmas, but international flights are still in hibernation.

Joyce is optimistic that international flights will begin operating next year. With the rollout of a vaccine, international borders could “open quite significantly” by the end of this year, failing that, by 2021.

Britain’s AstraZeneca and Oxford University said Monday, Nov. 23, that the CCP Virus vaccine they have produced is up to 90 percent effective, and because it does not require freezing, it will be easy to distribute.

The chief investigator for the drug’s trial Andrew Pollard from Oxford University, is confident of the vaccine’s efficacy. “These findings show that we have an effective vaccine that will save many lives,” he said, reports the NY Post.

Because the UK vaccine will only need refrigeration, it is a “more practical solution for use worldwide,” said Peter Horby, professor of Emerging Infectious Diseases and Global Health at Oxford.

“Importantly, from what we have heard, the vaccine seems to prevent infection, not just disease,” Horby said.

“This is important as the vaccine could reduce the spread of the virus as well as protect the vulnerable from severe disease,” he added.

Sign up to receive our latest news!

By submitting this form, I agree to the terms.